What Is Esomeprazole Magnesium?

Esmeprazole magnesium enteric-coated tablets, 1. Gastroesophageal reflux disease (GERD). 2. Treatment of erosive reflux esophagitis. 3. Long-term maintenance treatment to prevent recurrence in patients with esophagitis that has been cured. 4. Symptom control of gastroesophageal reflux disease (GERD) combined with appropriate antibacterial therapy to eradicate H. pylori. 5. Heal duodenal ulcers associated with Helicobacter pylori infection. 6. Prevent the recurrence of peptic ulcer associated with Helicobacter pylori. ^[1] .

Esmeprazole magnesium enteric-coated tablets, 1. Gastroesophageal reflux disease (GERD). 2. Treatment of erosive reflux esophagitis. 3. Long-term maintenance treatment to prevent recurrence in patients with esophagitis that has been cured. 4. Symptom control of gastroesophageal reflux disease (GERD) combined with appropriate antibacterial therapy to eradicate H. pylori. 5. Heal duodenal ulcers associated with Helicobacter pylori infection. 6. Prevent the recurrence of peptic ulcer associated with Helicobacter pylori. ^[1] .

Drug Name

Esmeprazole Magnesium Enteric-coated Tablets

Ingredients of ezomeprazole magnesium enteric-coated tablets

Esomeprazole magnesium

Esmeprazole Magnesium Enteric-coated Tablets

This product is an enteric-coated tablet.

Indications of ezomeprazole magnesium enteric-coated tablets

1. Gastroesophageal reflux disease (GERD). 2. Treatment of erosive reflux esophagitis. 3. Long-term maintenance treatment to prevent recurrence in patients with esophagitis that has been cured. 4. Symptom control of gastroesophageal reflux disease (GERD) combined with appropriate antibacterial therapy to eradicate H. pylori. 5. Heal duodenal ulcers associated with Helicobacter pylori infection. 6. Prevent the recurrence of peptic ulcer associated with Helicobacter pylori.

Esmeprazole magnesium enteric-coated tablets

The tablets should be swallowed whole with the liquid and should not be chewed or crushed.
1. The treatment of erosive reflux esophagitis, 40mg once a day, even for four weeks.
2. For patients with esophagitis that is not cured or persistent symptoms, it is recommended to take medication for another four weeks. Long-term maintenance treatment to prevent relapse in patients with cured esophagitis, 20 mg once daily.
3. Symptom control of gastroesophageal reflux disease (GERD) Patients without esophagitis 20 mg once daily. If the symptoms are not controlled after 4 weeks of treatment, the patient should be examined further. Once symptoms have resolved, subsequent symptom control can be achieved with immediate therapy, which is to take 20 mg orally once daily as needed.
4. Combined with appropriate antibacterial therapy to eradicate H. pylori and heal duodenal ulcers associated with H. pylori, prevent recurrence of peptic ulcers associated with H. pylori: Esomeprazole Magnesium Enteric-coated Tablets 20 mg + amoxicillin 1 g + clarithromycin 500 mg twice daily for 7 days.

Adverse effects of ezomeprazole magnesium enteric-coated tablets

The following adverse reactions have been identified or suspected in clinical trials of esomeprazole, none of which are dose-related. Common reactions 1. (1/100, 1/10): headache, abdominal pain, diarrhea, bloating, nausea / vomiting, constipation; rare reactions 2. (1/1000, 1/100): dermatitis, pruritus, urticaria, head Faint and dry mouth. Rare reactions 3. (1/10000, 1/1000): Allergic reactions, such as angioedema, allergic reactions, elevated liver transaminase. The following adverse reactions have been observed in the use of racemate (omeprazole), and therefore may also occur in the use of esomeprazole. 4. Central and peripheral nervous system: paresthesia, drowsiness, insomnia, dizziness. Reversible insanity, agitation, aggression, depression and hallucinations are mainly present in patients with severe illness.

Esmeprazole magnesium enteric-coated tablets contraindications

People who are allergic to esomeprazole, other benzimidazoles, or any other component of this product are contraindicated.

Precautions for esmeprazole magnesium enteric-coated tablets

When any alarm symptoms (such as significant unintentional weight loss, repeated vomiting, difficulty swallowing, bleeding or melena) are suspected, or a gastric ulcer is suspected, malignant tumors should be ruled out because of the use of Esomem Lazozole tablets can reduce symptoms and delay diagnosis. Patients treated with the drug for a long time (especially those who have used it for more than 1 year) should be monitored regularly. Renal function impairment Patients with impaired renal function do not need to adjust the dosage. For patients with severe renal insufficiency, due to limited experience with this drug, care should be taken during treatment (see Pharmacokinetics) in patients with mild to moderate hepatic impairment No dose adjustment is necessary. For patients with severe liver damage, the dosage of esomeprazole magnesium enteric-coated tablets is 20 mg (see Pharmacokinetics). The impact on the ability to drive and use machines has not been observed in this regard.

Esmeprazole magnesium enteric-coated tablets for pregnant and lactating women

Use with caution in pregnant women. It should not be used by lactating women.

Isoprazole magnesium enteric-coated tablets for children

Children should not use it.

Esmeprazole magnesium enteric-coated tablets for elderly

No dosage adjustment is needed for elderly patients.

Drug interactions of ezomeprazole magnesium enteric-coated tablets

Ketoconazole and itraconazole absorption decrease during esomeprazole treatment. When combined with diazepam, citalopram, imipramine, clomipramine, phenytoin, etc., these drugs may require dose reduction. Therefore, it is recommended to monitor the blood concentration of phenytoin when phenytoin is administered or discontinued during phenytoin therapy. No incompatibility.

Pharmacology and Toxicology of Esmeprazole Magnesium Enteric-coated Tablets

Based on routine studies of drug toxicity, genotoxicity, and reproductive toxicity, preclinical studies have not shown that esomeprazole is particularly harmful to humans. Carcinogenicity studies with racemic mixtures in rats have found gastric ECL cell proliferation and carcinoids. These effects on the stomach in rats are the result of persistent, significant hypergastrinemia. The latter is secondary to a decrease in gastric acid production and is seen in rats after chronic use of gastric acid secretion inhibitors.

Esmeprazole Magnesium Enteric-coated Tablets Storage

Sealed and stored below 30

Expiration date of ezomeprazole magnesium enteric-coated tablets

36 months